Table 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer | Synapse
October 2, 2025
Table 2 from Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Key Points
Response rates observed with the combination therapy indicate potential clinical benefit for patients.
The combination of gedatolisib, palbociclib, and letrozole was evaluated in hormone receptor-positive advanced breast cancer.
The analysis included patients with no prior systemic therapy, highlighting novel treatment avenues.
Findings support further investigation on the efficacy of this combination in managing advanced breast cancer.
Abstract
Response rates to gedatolisib + palbociclib + letrozole in the response evaluable set.